Toward “Serolomics”: Papillomavirus Serology Is Taking a Technologic Lead in High-Throughput Multiplexed Antibody Analysis
- 1 October 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (10) , 1768-1769
- https://doi.org/10.1373/clinchem.2005.055483
Abstract
The report by Waterboer et al. (1) in this issue represents one of the most thorough attempts to develop a high-throughput system for simultaneous analysis of antibodies against a large number of antigens. High-throughput assays, notably through various types of arrays, are increasingly important research tools in modern molecular medicine, but almost all the technologic development has been directed toward the analysis of DNA, RNA, and proteins (2), with more limited technologic progress in the field of serology. Will we see multiplexed antibody analysis, “serolomics”, arising as a new research field alongside genomics, RNomics, and proteomics? Measurements of groups of antibodies can have application in multiple areas of medicine. Analysis of a broad spectrum of autoantibodies is increasingly used in predictive diagnostics of autoimmune diseases (3), and autoantibodies against oncogene products are being studied in predictive oncology (4). The most interesting medical application, however, would be to rapidly assay the spectrum of microbiological agents to which a person has been exposed because past infections can be highly predictive of the risk of future diseases. Important examples include cardiovascular diseases, allergies, and cancer. Exposure to infections accounts for ∼17% of human cancers, with human papillomavirus (HPV) being one of the most important oncogenic …Keywords
This publication has 9 references indexed in Scilit:
- Multiplex Human Papillomavirus Serology Based on In Situ–Purified Glutathione S-Transferase Fusion ProteinsClinical Chemistry, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- High-throughput Methods for Measuring Autoantibodies in Systemic Lupus Erythematosus and other Autoimmune DiseasesAutoimmunity, 2004
- Molecular tools for a molecular medicine: analyzing genes, transcripts and proteins using padlock and proximity probesJournal of Molecular Recognition, 2004
- Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?Expert Reviews in Molecular Medicine, 2004
- Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex AssayClinical and Vaccine Immunology, 2003
- Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years laterAmerican Journal of Obstetrics and Gynecology, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological studyBritish Journal of Cancer, 1999